Skip to main content

Table 2 Direct comparison of regional citrate with heparin on adverse events

From: Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials

Adverse events No. of studies No. of patients RR(95%CI) Heterogeneity Test for effect (p value)
Citrate Heparin I2 (p value)
Bleeding events 10 (11, 13, 24, 25, 27, 28, 29, 32, 33, 34)a 405 405 0.31(0.19, 0.51) 0% (0.56) <0.00001
3 (12, 26, 31)b 140 138 0.23 (0.03, 1.97) 0% (0.75) 0.18
HIT 5 (11, 12, 13, 28, 33) 409 415 0.41 (0.19, 0.87) 0% (0.73) 0.02
Metabolic alkalosis 7(11, 13, 24, 27, 28, 29, 34) 289 301 0.84 (0.47, 1.49) 40% (0.14) 0.55
Hypocalcemia 7 (11, 24, 27, 28, 29, 33, 34) 310 311 3.96 (1.50, 10.43) 0% (1.00) 0.005
  1. CI confidence interval, HIT heparin induced thrombocytopenia, RR relative risk, a citrate versus systemic heparin; b citrate versus regional heparin